Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Breast Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 519 articles:
HTML format

Single Articles

    July 2020
  1. MEZEI T, Hajdu M, Czigleczki G, Lotz G, et al
    Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
    BMC Cancer. 2020;20:615.
    PubMed     Abstract available

    June 2020
  2. WANG J, Cai Y, Yu F, Ping Z, et al
    Body mass index increases the lymph node metastasis risk of breast cancer: a dose-response meta-analysis with 52904 subjects from 20 cohort studies.
    BMC Cancer. 2020;20:601.
    PubMed     Abstract available

  3. SIZEMORE G, McLaughlin S, Newman M, Brundage K, et al
    Opening large-conductance potassium channels selectively induced cell death of triple-negative breast cancer.
    BMC Cancer. 2020;20:595.
    PubMed     Abstract available

  4. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer.
    BMC Cancer. 2020;20:598.
    PubMed     Abstract available

  5. SONG Y, Zhao B, Xu Y, Ren X, et al
    Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer.
    BMC Cancer. 2020;20:584.
    PubMed     Abstract available

  6. FENG Q, Hu Q, Liu Y, Yang T, et al
    Diagnosis of triple negative breast cancer based on radiomics signatures extracted from preoperative contrast-enhanced chest computed tomography.
    BMC Cancer. 2020;20:579.
    PubMed     Abstract available

  7. ZHANG Y, Yu C
    Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer.
    BMC Cancer. 2020;20:575.
    PubMed     Abstract available

  8. REPO H, Loyttyniemi E, Kurki S, Kallio L, et al
    A prognostic model based on cell-cycle control predicts outcome of breast cancer patients.
    BMC Cancer. 2020;20:558.
    PubMed     Abstract available

  9. HAGERLING C, Owyong M, Sitarama V, Wang CY, et al
    LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target.
    BMC Cancer. 2020;20:542.
    PubMed     Abstract available

  10. ROSATI R, Oppat K, Huang Y, Kim S, et al
    Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models.
    BMC Cancer. 2020;20:512.
    PubMed     Abstract available

  11. SANGES F, Floris M, Cossu-Rocca P, Muroni MR, et al
    Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis.
    BMC Cancer. 2020;20:491.
    PubMed     Abstract available

  12. YANG L, Wang S, Zhang L, Sheng C, et al
    Performance of ultrasonography screening for breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:499.
    PubMed     Abstract available

    May 2020
  13. OLSSON MOLLER U, Ryden L, Malmstrom M
    Systematic screening as a tool for individualized rehabilitation following primary breast cancer treatment: study protocol for the ReScreen randomized controlled trial.
    BMC Cancer. 2020;20:484.
    PubMed     Abstract available

  14. BARROS-OLIVEIRA MDC, Costa-Silva DR, Campos-Verdes LC, Pereira RO, et al
    CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse.
    BMC Cancer. 2020;20:480.
    PubMed     Abstract available

  15. SINGLETON DC, Dechaume AL, Murray PM, Katt WP, et al
    Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    BMC Cancer. 2020;20:470.
    PubMed     Abstract available

  16. FARAZ M, Tellstrom A, Ardnor CE, Grankvist K, et al
    LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer.
    BMC Cancer. 2020;20:459.
    PubMed     Abstract available

  17. WESOLOWSKI R, Stiff A, Quiroga D, McQuinn C, et al
    Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    BMC Cancer. 2020;20:445.
    PubMed     Abstract available

  18. NAUGHTON MJ, Beverly Hery CM, Janse SA, Naftalis EZ, et al
    Prevalence and correlates of job and insurance problems among young breast cancer survivors within 18 months of diagnosis.
    BMC Cancer. 2020;20:432.
    PubMed     Abstract available

    Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
    BMC Cancer. 2020;20:440.
    PubMed     Abstract available

  20. IWASE T, Harano K, Masuda H, Kida K, et al
    Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    BMC Cancer. 2020;20:430.
    PubMed     Abstract available

  21. ALFARSI LH, El Ansari R, Craze ML, Masisi BK, et al
    PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.
    BMC Cancer. 2020;20:425.
    PubMed     Abstract available

  22. OMARINI C, Piacentini F, Sperduti I, Barbolini M, et al
    Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and
    BMC Cancer. 2020;20:418.
    PubMed     Abstract available

  23. BJELIC-RADISIC V, Fitzal F, Knauer M, Steger G, et al
    Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial.
    BMC Cancer. 2020;20:392.
    PubMed     Abstract available

  24. VAN DER MERWE NC, Oosthuizen J, Theron M, Chong G, et al
    The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
    BMC Cancer. 2020;20:391.
    PubMed     Abstract available

  25. ADAMS EJ, Asad S, Reinbolt R, Collier KA, et al
    Metastatic breast cancer patient perceptions of somatic tumor genomic testing.
    BMC Cancer. 2020;20:389.
    PubMed     Abstract available

  26. YOON SH, Kim HS, Kim RN, Jung SY, et al
    NAD(P)-dependent steroid dehydrogenase-like is involved in breast cancer cell growth and metastasis.
    BMC Cancer. 2020;20:375.
    PubMed     Abstract available

  27. KIM SH, Choe YH, Han AR, Yeon GJ, et al
    Design of a randomized controlled trial of a partnership-based, needs-tailored self-management support intervention for post-treatment breast cancer survivors.
    BMC Cancer. 2020;20:367.
    PubMed     Abstract available

    April 2020
  28. BLOOM MJ, Jarrett AM, Triplett TA, Syed AK, et al
    Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
    BMC Cancer. 2020;20:359.
    PubMed     Abstract available

  29. MCCARTHY AM, Kumar NP, He W, Regan S, et al
    Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
    BMC Cancer. 2020;20:347.
    PubMed     Abstract available

  30. MERY B, Fouilloux A, Rowinski E, Catella-Chatron J, et al
    Cardiovascular disease events within 5 years after a diagnosis of breast cancer.
    BMC Cancer. 2020;20:337.
    PubMed     Abstract available

  31. RAITER A, Lipovetzki J, Lubin I, Yerushalmi R, et al
    GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.
    BMC Cancer. 2020;20:333.
    PubMed     Abstract available

  32. TRILLA-FUERTES L, Gamez-Pozo A, Lopez-Camacho E, Prado-Vazquez G, et al
    Computational models applied to metabolomics data hints at the relevance of glutamine metabolism in breast cancer.
    BMC Cancer. 2020;20:307.
    PubMed     Abstract available

  33. DECKER T, Soling U, Hahn A, Maintz C, et al
    Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positiv
    BMC Cancer. 2020;20:286.
    PubMed     Abstract available

  34. LIU Z, Li R, Liang K, Chen J, et al
    Value of digital mammography in predicting lymphovascular invasion of breast cancer.
    BMC Cancer. 2020;20:274.
    PubMed     Abstract available

    March 2020
  35. VAHIDI Y, Bagheri M, Ghaderi A, Faghih Z, et al
    CD8-positive memory T cells in tumor-draining lymph nodes of patients with breast cancer.
    BMC Cancer. 2020;20:257.
    PubMed     Abstract available

  36. YANG F, Huang X, Sun C, Li J, et al
    Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
    BMC Cancer. 2020;20:255.
    PubMed     Abstract available

  37. RAINEY L, van der Waal D, Jervaeus A, Donnelly LS, et al
    European women's perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: a qualitative study.
    BMC Cancer. 2020;20:247.
    PubMed     Abstract available

  38. HAN BY, Li XG, Zhao HY, Hu X, et al
    Clinical features and survival of pregnancy-associated breast cancer: a retrospective study of 203 cases in China.
    BMC Cancer. 2020;20:244.
    PubMed     Abstract available

  39. CAPUTO R, Cazzaniga ME, Sbrana A, Torrisi R, et al
    Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
    BMC Cancer. 2020;20:232.
    PubMed     Abstract available

  40. DING N, Huang J, Li N, Yuan J, et al
    Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
    BMC Cancer. 2020;20:235.
    PubMed     Abstract available

  41. FLORIS M, Sanna D, Castiglia P, Putzu C, et al
    MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North Sardinia.
    BMC Cancer. 2020;20:234.
    PubMed     Abstract available

  42. SAN MIGUEL Y, Gomez SL, Murphy JD, Schwab RB, et al
    Age-related differences in breast cancer mortality according to race/ethnicity, insurance, and socioeconomic status.
    BMC Cancer. 2020;20:228.
    PubMed     Abstract available

  43. MEALEY NE, O'Sullivan DE, Pader J, Ruan Y, et al
    Mutational landscape differences between young-onset and older-onset breast cancer patients.
    BMC Cancer. 2020;20:212.
    PubMed     Abstract available

  44. GAO G, Wang Z, Qu X, Zhang Z, et al
    Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:179.
    PubMed     Abstract available

  45. SUN Z, Lan X, Xu S, Li S, et al
    Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
    BMC Cancer. 2020;20:180.
    PubMed     Abstract available

  46. KHIL L, Heidrich J, Wellmann I, Kaab-Sanyal V, et al
    Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study.
    BMC Cancer. 2020;20:174.
    PubMed     Abstract available

  47. ZHANG XM, Dou QL, Zeng Y, Yang Y, et al
    Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review.
    BMC Cancer. 2020;20:172.
    PubMed     Abstract available

    February 2020
  48. OBA T, Maeno K, Takekoshi D, Ono M, et al
    Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer.
    BMC Cancer. 2020;20:160.
    PubMed     Abstract available

  49. LI L, Zhang H, Wang L, Xie C, et al
    A retrospective analysis on metastatic rate of the internal mammary lymph node and its clinical significance in adjuvant radiotherapy of breast cancer patients.
    BMC Cancer. 2020;20:153.
    PubMed     Abstract available

  50. KALECKY K, Modisette R, Pena S, Cho YR, et al
    Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
    BMC Cancer. 2020;20:141.
    PubMed     Abstract available

  51. EE C, Cave AE, Naidoo D, Bilinski K, et al
    Weight before and after a diagnosis of breast cancer or ductal carcinoma in situ: a national Australian survey.
    BMC Cancer. 2020;20:113.
    PubMed     Abstract available

  52. EPPENBERGER-CASTORI S, Klingbiel D, Ruhstaller T, Dietrich D, et al
    Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
    BMC Cancer. 2020;20:114.
    PubMed     Abstract available

  53. ZHOU J, Lu J, Gao C, Zeng J, et al
    Predicting the response to neoadjuvant chemotherapy for breast cancer: wavelet transforming radiomics in MRI.
    BMC Cancer. 2020;20:100.
    PubMed     Abstract available

  54. GINZAC A, Barres B, Chanchou M, Gadea E, et al
    A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients.
    BMC Cancer. 2020;20:96.
    PubMed     Abstract available

  55. NI-JIA-TI MY, Ai-Hai-Ti DL, Huo-Jia AS, Wu-Mai-Er PL, et al
    Development of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer.
    BMC Cancer. 2020;20:94.
    PubMed     Abstract available

    January 2020
  56. SOLIMAN H, Shah V, Srkalovic G, Mahtani R, et al
    MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
    BMC Cancer. 2020;20:81.
    PubMed     Abstract available

  57. BACOLOD MD, Huang J, Giardina SF, Feinberg PB, et al
    Prediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detection.
    BMC Cancer. 2020;20:85.
    PubMed     Abstract available

  58. YAMAZAKI R, Inokuchi M, Ishikawa S, Ayabe T, et al
    Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study.
    BMC Cancer. 2020;20:67.
    PubMed     Abstract available

  59. NILSSON G, Kannius-Janson M
    Correction to: Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling.
    BMC Cancer. 2020;20:55.
    PubMed     Abstract available

  60. TWELVES C, Cheeseman S, Sopwith W, Thompson M, et al
    Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.
    BMC Cancer. 2020;20:53.
    PubMed     Abstract available

  61. HE J, Tsang JY, Xu X, Li J, et al
    AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer.
    BMC Cancer. 2020;20:18.
    PubMed     Abstract available

  62. SHAHI THAKURI P, Gupta M, Singh S, Joshi R, et al
    Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling.
    BMC Cancer. 2020;20:4.
    PubMed     Abstract available

    December 2019
  63. DAGHER E, Royer V, Buchet P, Abadie J, et al
    Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    BMC Cancer. 2019;19:1267.
    PubMed     Abstract available

  64. SKARPING I, Fornvik D, Sartor H, Heide-Jorgensen U, et al
    Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer.
    BMC Cancer. 2019;19:1272.
    PubMed     Abstract available

  65. AL-EITAN LN, Rababa'h DM, Alghamdi MA, Khasawneh RH, et al
    Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: a case-control study.
    BMC Cancer. 2019;19:1257.
    PubMed     Abstract available

  66. GLASER RL, York AE, Dimitrakakis C
    Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study.
    BMC Cancer. 2019;19:1271.
    PubMed     Abstract available

  67. KIZILBOGA T, Baskale EA, Yildiz J, Akcay IM, et al
    Bag-1 stimulates Bad phosphorylation through activation of Akt and Raf kinases to mediate cell survival in breast cancer.
    BMC Cancer. 2019;19:1254.
    PubMed     Abstract available

  68. CAMACHO F, Anderson R, Kimmick G
    Investigating confounders of the association between survival and adjuvant radiation therapy after breast conserving surgery in a sample of elderly breast Cancer patients in Appalachia.
    BMC Cancer. 2019;19:1228.
    PubMed     Abstract available

  69. HOSHINA H, Takei H
    Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.
    BMC Cancer. 2019;19:1217.
    PubMed     Abstract available

  70. MARCZYK M, Fu C, Lau R, Du L, et al
    The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues.
    BMC Cancer. 2019;19:1189.
    PubMed     Abstract available

  71. LENDE TH, Austdal M, Bathen TF, Varhaugvik AE, et al
    Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study.
    BMC Cancer. 2019;19:1183.
    PubMed     Abstract available

  72. HARVIE M, Pegington M, French D, Cooper G, et al
    Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials.
    BMC Cancer. 2019;19:1089.
    PubMed     Abstract available

  73. SUN X, Qu Q, Lao Y, Zhang M, et al
    Tumor suppressor HIC1 is synergistically compromised by cancer-associated fibroblasts and tumor cells through the IL-6/pSTAT3 axis in breast cancer.
    BMC Cancer. 2019;19:1180.
    PubMed     Abstract available

  74. YUAN CL, Jiang XM, Yi Y, E JF, et al
    Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing.
    BMC Cancer. 2019;19:1171.
    PubMed     Abstract available

  75. ALVES WEFM, Bonatelli M, Dufloth R, Kerr LM, et al
    CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
    BMC Cancer. 2019;19:1173.
    PubMed     Abstract available

  76. LEE CH, Hsieh JC, Wu TM, Yeh TS, et al
    Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer.
    BMC Cancer. 2019;19:1167.
    PubMed     Abstract available

    November 2019
  77. TESAURO C, Simonsen AK, Andersen MB, Petersen KW, et al
    Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    BMC Cancer. 2019;19:1158.
    PubMed     Abstract available

  78. YAMAGISHI Y, Koiwai T, Yamasaki T, Einama T, et al
    Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer.
    BMC Cancer. 2019;19:1146.
    PubMed     Abstract available

  79. GARCIA-GARCIA T, Carmona-Bayonas A, Jimenez-Fonseca P, Jara C, et al
    Biopsychosocial and clinical characteristics in patients with resected breast and colon cancer at the beginning and end of adjuvant treatment.
    BMC Cancer. 2019;19:1143.
    PubMed     Abstract available

  80. TJENSVOLL K, Nordgard O, Skjaeveland M, Oltedal S, et al
    Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients.
    BMC Cancer. 2019;19:1131.
    PubMed     Abstract available

  81. KRAWCZYK N, Neubacher M, Meier-Stiegen F, Neubauer H, et al
    Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
    BMC Cancer. 2019;19:1101.
    PubMed     Abstract available

  82. WANG R, Zhu Y, Liu X, Liao X, et al
    The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.
    BMC Cancer. 2019;19:1091.
    PubMed     Abstract available

  83. WANG C, Li X, Su S, Wang X, et al
    Factors analysis on the use of key quality indicators for narrowing the gap of quality of care of breast cancer.
    BMC Cancer. 2019;19:1099.
    PubMed     Abstract available

  84. LU S, Yakirevich E, Wang LJ, Resnick MB, et al
    Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.
    BMC Cancer. 2019;19:1085.
    PubMed     Abstract available

  85. LENDE TH, Austdal M, Varhaugvik AE, Skaland I, et al
    Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients horizontal line a randomized trial.
    BMC Cancer. 2019;19:1076.
    PubMed     Abstract available

  86. PANDY JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF, et al
    Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
    BMC Cancer. 2019;19:1065.
    PubMed     Abstract available

  87. LI S, Yan W, Yang X, Chen L, et al
    Less micrometastatic risk related to circulating tumor cells after endoscopic breast cancer surgery compared to open surgery.
    BMC Cancer. 2019;19:1070.
    PubMed     Abstract available

  88. JOHNSSON A, Demmelmaier I, Sjovall K, Wagner P, et al
    A single exercise session improves side-effects of chemotherapy in women with breast cancer: an observational study.
    BMC Cancer. 2019;19:1073.
    PubMed     Abstract available

  89. SUROV A, Chang YW, Li L, Martincich L, et al
    Apparent diffusion coefficient cannot predict molecular subtype and lymph node metastases in invasive breast cancer: a multicenter analysis.
    BMC Cancer. 2019;19:1043.
    PubMed     Abstract available

  90. ZHU C, Menyhart O, Gyorffy B, He X, et al
    The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy.
    BMC Cancer. 2019;19:1046.
    PubMed     Abstract available

  91. DE AMICIS F, Chiodo C, Morelli C, Casaburi I, et al
    AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
    BMC Cancer. 2019;19:1038.
    PubMed     Abstract available

  92. HILL DP, Harper A, Malcolm J, McAndrews MS, et al
    Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
    BMC Cancer. 2019;19:1039.
    PubMed     Abstract available

  93. BAZAN F, Dobi E, Royer B, Curtit E, et al
    Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.
    BMC Cancer. 2019;19:1029.
    PubMed     Abstract available

  94. BOLANDGHAMAT POUR Z, Nourbakhsh M, Mousavizadeh K, Madjd Z, et al
    Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.
    BMC Cancer. 2019;19:1027.
    PubMed     Abstract available

  95. ZHAO CL, Singh K, Brodsky AS, Lu S, et al
    Stromal ColXalpha1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.
    BMC Cancer. 2019;19:1036.
    PubMed     Abstract available

    October 2019
  96. HANAMURA T, Ohno K, Hokibara S, Murasawa H, et al
    Clinical significance of serum PSA in breast cancer patients.
    BMC Cancer. 2019;19:1021.
    PubMed     Abstract available

  97. GOOSSENS M, De Brabander I, De Greve J, Van Ongeval C, et al
    Flemish breast cancer screening programme: 15 years of key performance indicators (2002-2016).
    BMC Cancer. 2019;19:1012.
    PubMed     Abstract available

  98. ZHANG W, Yang S, Liu J, Bao L, et al
    Screening antiproliferative drug for breast cancer from bisbenzylisoquinoline alkaloid tetrandrine and fangchinoline derivatives by targeting BLM helicase.
    BMC Cancer. 2019;19:1009.
    PubMed     Abstract available

  99. BARTON M, Santucci-Pereira J, Vaccaro OG, Nguyen T, et al
    BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis.
    BMC Cancer. 2019;19:994.
    PubMed     Abstract available

  100. SUAMI H, Heydon-White A, Mackie H, Czerniec S, et al
    A new indocyanine green fluorescence lymphography protocol for identification of the lymphatic drainage pathway for patients with breast cancer-related lymphoedema.
    BMC Cancer. 2019;19:985.
    PubMed     Abstract available

  101. PU T, Shui R, Shi J, Liang Z, et al
    External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
    BMC Cancer. 2019;19:978.
    PubMed     Abstract available

  102. CHEN S, Liang Y, Feng Z, Wang M, et al
    Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:973.
    PubMed     Abstract available

  103. IWASA T, Tsurutani J, Watanabe S, Kato R, et al
    Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
    BMC Cancer. 2019;19:962.
    PubMed     Abstract available

  104. ZHANG JJ, Zhang WC, An CX, Li XM, et al
    Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer.
    BMC Cancer. 2019;19:956.
    PubMed     Abstract available

  105. SUROV A, Meyer HJ, Wienke A
    Can apparent diffusion coefficient (ADC) distinguish breast cancer from benign breast findings? A meta-analysis based on 13 847 lesions.
    BMC Cancer. 2019;19:955.
    PubMed     Abstract available

  106. ZHOU Y, Li Y, Mao F, Zhang J, et al
    Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer.
    BMC Cancer. 2019;19:939.
    PubMed     Abstract available

    September 2019
  107. MCCULLOUGH LE, Collin LJ, Conway K, White AJ, et al
    Reproductive characteristics are associated with gene-specific promoter methylation status in breast cancer.
    BMC Cancer. 2019;19:926.
    PubMed     Abstract available

  108. ZHANG J, Liu Y, Zang M, Zhu S, et al
    Lentivirus-mediated CDglyTK gene-modified free flaps by intra-artery perfusion show targeted therapeutic efficacy in rat model of breast cancer.
    BMC Cancer. 2019;19:921.
    PubMed     Abstract available

  109. BORM KJ, Schonknecht C, Nestler A, Oechsner M, et al
    Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients.
    BMC Cancer. 2019;19:907.
    PubMed     Abstract available

  110. DANIELS B, Kiely BE, Tang M, Tervonen H, et al
    Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015).
    BMC Cancer. 2019;19:909.
    PubMed     Abstract available

  111. SCHMID S, Klingbiel D, Aebi S, Goldhirsch A, et al
    Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
    BMC Cancer. 2019;19:902.
    PubMed     Abstract available

  112. DE HAAN R, van Werkhoven E, van den Heuvel MM, Peulen HMU, et al
    Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
    BMC Cancer. 2019;19:901.
    PubMed     Abstract available

  113. XIAO B, Chen D, Zhou Q, Hang J, et al
    Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.
    BMC Cancer. 2019;19:891.
    PubMed     Abstract available

  114. BAYARMAA B, Wu Z, Peng J, Wang Y, et al
    Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
    BMC Cancer. 2019;19:877.
    PubMed     Abstract available

  115. KRZYZANOWSKA MK, Julian JA, Powis M, Howell D, et al
    Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
    BMC Cancer. 2019;19:884.
    PubMed     Abstract available

  116. MCQUERRY JA, Jenkins DF, Yost SE, Zhang Y, et al
    Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.
    BMC Cancer. 2019;19:881.
    PubMed     Abstract available

  117. REN ZJ, Cao DH, Zhang Q, Ren PW, et al
    First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:871.
    PubMed     Abstract available

    August 2019
  118. KIM WH, Kim HJ, Kim SH, Jung JH, et al
    Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study.
    BMC Cancer. 2019;19:859.
    PubMed     Abstract available

  119. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available

  120. YOU Q, Fang Y, Li C, Tan Y, et al
    Multiple metastases of bones and sigmoid colon after mastectomy for ductal carcinoma in situ of the breast: a case report.
    BMC Cancer. 2019;19:844.
    PubMed     Abstract available

  121. CHAE BJ, Lee J, Lee SK, Shin HJ, et al
    Unmet needs and related factors of Korean breast cancer survivors: a multicenter, cross-sectional study.
    BMC Cancer. 2019;19:839.
    PubMed     Abstract available

  122. WONDIMAGEGNEHU A, Abebe W, Abraha A, Teferra S, et al
    Depression and social support among breast cancer patients in Addis Ababa, Ethiopia.
    BMC Cancer. 2019;19:836.
    PubMed     Abstract available

  123. ZENG L, Deng X, Zhong J, Yuan L, et al
    Prognostic value of biomarkers EpCAM and alphaB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.
    BMC Cancer. 2019;19:831.
    PubMed     Abstract available

  124. WAHABI K, Perwez A, Kamarudheen S, Bhat ZI, et al
    Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
    BMC Cancer. 2019;19:820.
    PubMed     Abstract available

  125. NUR U, El Reda D, Hashim D, Weiderpass E, et al
    A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women's lifestyle and health cohort.
    BMC Cancer. 2019;19:807.
    PubMed     Abstract available

  126. MA H, Malone KE, McDonald JA, Marchbanks PA, et al
    Pre-diagnosis alcohol consumption and mortality risk among black women and white women with invasive breast cancer.
    BMC Cancer. 2019;19:800.
    PubMed     Abstract available

  127. SEPAHI I, Faust U, Sturm M, Bosse K, et al
    Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
    BMC Cancer. 2019;19:787.
    PubMed     Abstract available

  128. KIM CY, Kim N, Choung HK, In Khwarg S, et al
    Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla(R), T-DM1) administration: a case report.
    BMC Cancer. 2019;19:774.
    PubMed     Abstract available

  129. GOMES CP, Nobrega-Pereira S, Domingues-Silva B, Rebelo K, et al
    An antisense transcript mediates MALAT1 response in human breast cancer.
    BMC Cancer. 2019;19:771.
    PubMed     Abstract available

    July 2019
  130. BARRENO L, Caceres S, Alonso-Diez A, Vicente-Montana A, et al
    Vasculogenic mimicry-associated ultrastructural findings in human and canine inflammatory breast cancer cell lines.
    BMC Cancer. 2019;19:750.
    PubMed     Abstract available

  131. LATTANZIO R, Iezzi M, Sala G, Tinari N, et al
    PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
    BMC Cancer. 2019;19:747.
    PubMed     Abstract available

  132. KOCIK J, Pajaczek M, Kryczka T
    Worse survival in breast cancer in elderly may not be due to underutilization of medical procedures as observed upon changing healthcare system in Poland.
    BMC Cancer. 2019;19:749.
    PubMed     Abstract available

  133. WANG H, Tan Z, Hu H, Liu H, et al
    microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1.
    BMC Cancer. 2019;19:738.
    PubMed     Abstract available

  134. CARAYOL M, Ninot G, Senesse P, Bleuse JP, et al
    Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial.
    BMC Cancer. 2019;19:737.
    PubMed     Abstract available

  135. TIAINEN L, Korhonen EA, Leppanen VM, Luukkaala T, et al
    High baseline Tie1 level predicts poor survival in metastatic breast cancer.
    BMC Cancer. 2019;19:732.
    PubMed     Abstract available

  136. QIU Y, Wang L, Zhong X, Li L, et al
    A multiple breast cancer stem cell model to predict recurrence of T1-3, N0 breast cancer.
    BMC Cancer. 2019;19:729.
    PubMed     Abstract available

  137. ESPARZA-LOPEZ J, Alvarado-Munoz JF, Escobar-Arriaga E, Ulloa-Aguirre A, et al
    Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-kappaB pathways.
    BMC Cancer. 2019;19:728.
    PubMed     Abstract available

  138. ZAYAS-VILLANUEVA OA, Campos-Acevedo LD, Lugo-Trampe JJ, Hernandez-Barajas D, et al
    Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    BMC Cancer. 2019;19:722.
    PubMed     Abstract available

  139. CASEY MC, Prakash A, Holian E, McGuire A, et al
    Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer.
    BMC Cancer. 2019;19:712.
    PubMed     Abstract available

  140. LAIBLE M, Hartmann K, Gurtler C, Anzeneder T, et al
    Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
    BMC Cancer. 2019;19:694.
    PubMed     Abstract available

  141. DANZINGER S, Tan YY, Rudas M, Kastner MT, et al
    Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    BMC Cancer. 2019;19:695.
    PubMed     Abstract available

  142. MARKL B, Kazik M, Harbeck N, Jakubowicz E, et al
    Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer.
    BMC Cancer. 2019;19:692.
    PubMed     Abstract available

  143. LIM SM, Han Y, Kim SI, Park HS, et al
    Utilization of bioelectrical impedance analysis for detection of lymphedema in breast Cancer survivors: a prospective cross sectional study.
    BMC Cancer. 2019;19:669.
    PubMed     Abstract available

  144. MARTIN-PARDILLOS A, Valls Chiva A, Bande Vargas G, Hurtado Blanco P, et al
    The role of clonal communication and heterogeneity in breast cancer.
    BMC Cancer. 2019;19:666.
    PubMed     Abstract available

  145. MCBRIDE ML, Groome PA, Decker K, Kendell C, et al
    Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study.
    BMC Cancer. 2019;19:659.
    PubMed     Abstract available

  146. SINGLETON A, Partridge SR, Raeside R, Regimbal M, et al
    A text message intervention to support women's physical and mental health after breast cancer treatments (EMPOWER-SMS): a randomised controlled trial protocol.
    BMC Cancer. 2019;19:660.
    PubMed     Abstract available

  147. LEE K, Kang I, Mack WJ, Mortimer J, et al
    Feasibility of high intensity interval training in patients with breast Cancer undergoing anthracycline chemotherapy: a randomized pilot trial.
    BMC Cancer. 2019;19:653.
    PubMed     Abstract available

  148. ADLARD KN, Jenkins DG, Salisbury CE, Bolam KA, et al
    Peer support for the maintenance of physical activity and health in cancer survivors: the PEER trial - a study protocol of a randomised controlled trial.
    BMC Cancer. 2019;19:656.
    PubMed     Abstract available

    June 2019
  149. HANNAFON BN, Cai A, Calloway CL, Xu YF, et al
    miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study.
    BMC Cancer. 2019;19:642.
    PubMed     Abstract available

  150. CHEN JH, Huang WC, Bamodu OA, Chang PM, et al
    Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
    BMC Cancer. 2019;19:634.
    PubMed     Abstract available

  151. MORAN O, Eisen A, Demsky R, Blackmore K, et al
    Predictors of mammographic density among women with a strong family history of breast cancer.
    BMC Cancer. 2019;19:631.
    PubMed     Abstract available

  152. MAJID S, Ryden L, Manjer J
    Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
    BMC Cancer. 2019;19:626.
    PubMed     Abstract available

  153. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer.
    BMC Cancer. 2019;19:615.
    PubMed     Abstract available

  154. PEREZ EA, de Haas SL, Eiermann W, Barrios CH, et al
    Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    BMC Cancer. 2019;19:620.
    PubMed     Abstract available

  155. WALLWIENER M, Nabieva N, Feisst M, Fehm T, et al
    Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
    BMC Cancer. 2019;19:611.
    PubMed     Abstract available

  156. DIHGE L, Ohlsson M, Eden P, Bendahl PO, et al
    Artificial neural network models to predict nodal status in clinically node-negative breast cancer.
    BMC Cancer. 2019;19:610.
    PubMed     Abstract available

  157. GEBREHIWOT AG, Melka DS, Kassaye YM, Gemechu T, et al
    Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women.
    BMC Cancer. 2019;19:588.
    PubMed     Abstract available

  158. RESENDE U, Cabello C, Ramalho SOB, Zeferino LC, et al
    Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    BMC Cancer. 2019;19:601.
    PubMed     Abstract available

  159. WANG C, Xu C, Niu R, Hu G, et al
    MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147.
    BMC Cancer. 2019;19:577.
    PubMed     Abstract available

  160. KUMLER I, Balslev E, Stenvang J, Brunner N, et al
    Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
    BMC Cancer. 2019;19:573.
    PubMed     Abstract available

  161. SCHWARTZBERG L, McIntyre K, Wilks S, Puhalla S, et al
    Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
    BMC Cancer. 2019;19:578.
    PubMed     Abstract available

  162. TORDJMAN J, Majumder M, Amiri M, Hasan A, et al
    Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
    BMC Cancer. 2019;19:561.
    PubMed     Abstract available

  163. KAREDATH T, Ahmed I, Al Ameri W, Al-Dasim FM, et al
    Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes.
    BMC Cancer. 2019;19:565.
    PubMed     Abstract available

  164. VRINTEN C, Gallagher A, Waller J, Marlow LAV, et al
    Cancer stigma and cancer screening attendance: a population based survey in England.
    BMC Cancer. 2019;19:566.
    PubMed     Abstract available

  165. ZHANG J, Li K, Zhang Y, Lu R, et al
    Deletion of sorting nexin 27 suppresses proliferation in highly aggressive breast cancer MDA-MB-231 cells in vitro and in vivo.
    BMC Cancer. 2019;19:555.
    PubMed     Abstract available

  166. LALL K, Lepamets M, Palover M, Esko T, et al
    Polygenic prediction of breast cancer: comparison of genetic predictors and implications for risk stratification.
    BMC Cancer. 2019;19:557.
    PubMed     Abstract available

  167. BUSTAMANTE EDUARDO M, Popovici V, Imboden S, Aebi S, et al
    Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    BMC Cancer. 2019;19:549.
    PubMed     Abstract available

  168. CAO WM, Zheng YB, Gao Y, Ding XW, et al
    Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women.
    BMC Cancer. 2019;19:551.
    PubMed     Abstract available

  169. YANG Y, Wang Y, Deng H, Tan C, et al
    Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
    BMC Cancer. 2019;19:541.
    PubMed     Abstract available

  170. CHANG VC, Cotterchio M, Khoo E
    Iron intake, body iron status, and risk of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:543.
    PubMed     Abstract available

  171. TSAOUSIS GN, Papadopoulou E, Apessos A, Agiannitopoulos K, et al
    Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    BMC Cancer. 2019;19:535.
    PubMed     Abstract available

    May 2019
  172. PEREZ EA, de Haas SL, Eiermann W, Barrios CH, et al
    Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    BMC Cancer. 2019;19:517.
    PubMed     Abstract available

  173. HOLLECZEK B, Stegmaier C, Radosa JC, Solomayer EF, et al
    Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany.
    BMC Cancer. 2019;19:520.
    PubMed     Abstract available

  174. KIKUCHI-KOIKE R, Nagasaka K, Tsuda H, Ishii Y, et al
    Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer.
    BMC Cancer. 2019;19:521.
    PubMed     Abstract available

  175. PLAZA-DIAZ J, Alvarez-Mercado AI, Ruiz-Marin CM, Reina-Perez I, et al
    Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study.
    BMC Cancer. 2019;19:495.
    PubMed     Abstract available

  176. RUTKOVSKY AC, Yeh ES, Guest ST, Findlay VJ, et al
    Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
    BMC Cancer. 2019;19:491.
    PubMed     Abstract available

  177. OLSSON MOLLER U, Beck I, Ryden L, Malmstrom M, et al
    A comprehensive approach to rehabilitation interventions following breast cancer treatment - a systematic review of systematic reviews.
    BMC Cancer. 2019;19:472.
    PubMed     Abstract available

  178. PEISL S, Zimmermann S, Camey B, Betticher D, et al
    Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg.
    BMC Cancer. 2019;19:469.
    PubMed     Abstract available

  179. YANG X, Zhang K, Zhang C, Peng R, et al
    Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    BMC Cancer. 2019;19:465.
    PubMed     Abstract available

  180. BURM R, Thewes B, Rodwell L, Kievit W, et al
    Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial.
    BMC Cancer. 2019;19:462.
    PubMed     Abstract available

  181. WANG K, Wang G, Huang S, Luo A, et al
    Association between TIMP-2 gene polymorphism and breast cancer in Han Chinese women.
    BMC Cancer. 2019;19:446.
    PubMed     Abstract available

  182. ZHENG A, Zhang L, Song X, Wang Y, et al
    Clinical implications of a novel prognostic factor AIFM3 in breast cancer patients.
    BMC Cancer. 2019;19:451.
    PubMed     Abstract available

  183. YI Z, Ma F, Liu B, Guan X, et al
    Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    BMC Cancer. 2019;19:442.
    PubMed     Abstract available

  184. MCANENA P, Tanriverdi K, Curran C, Gilligan K, et al
    Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    BMC Cancer. 2019;19:436.
    PubMed     Abstract available

  185. VALE DB, Filho CC, Shinzato JY, Spreafico FS, et al
    Downstaging in opportunistic breast cancer screening in Brazil: a temporal trend analysis.
    BMC Cancer. 2019;19:432.
    PubMed     Abstract available

  186. ARAS S, Maroun MC, Song Y, Bandyopadhyay S, et al
    Mitochondrial autoimmunity and MNRR1 in breast carcinogenesis.
    BMC Cancer. 2019;19:411.
    PubMed     Abstract available

    April 2019
  187. ZAKRZEWSKI F, Gieldon L, Rump A, Seifert M, et al
    Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    BMC Cancer. 2019;19:396.
    PubMed     Abstract available

  188. DERESSA BT, Cihoric N, Badra EV, Tsikkinis A, et al
    Breast cancer care in northern Ethiopia - cross-sectional analysis.
    BMC Cancer. 2019;19:393.
    PubMed     Abstract available

  189. LEE J, Lee EH, Park HY, Kim WW, et al
    Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer.
    BMC Cancer. 2019;19:388.
    PubMed     Abstract available

  190. ZHAO Y, Luo H, Zhang X, Bianba T, et al
    Clinicopathological characteristics and health care for Tibetan women with breast cancer: a cross-sectional survey.
    BMC Cancer. 2019;19:380.
    PubMed     Abstract available

  191. LU L, Huang H, Zhou J, Ma W, et al
    BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
    BMC Cancer. 2019;19:387.
    PubMed     Abstract available

  192. SALERNO EA, Rowland K, Kramer AF, McAuley E, et al
    Acute aerobic exercise effects on cognitive function in breast cancer survivors: a randomized crossover trial.
    BMC Cancer. 2019;19:371.
    PubMed     Abstract available

  193. CHAO X, Chen K, Zeng J, Bi Z, et al
    Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:372.
    PubMed     Abstract available

  194. RUFFALO M, Bar-Joseph Z
    Protein interaction disruption in cancer.
    BMC Cancer. 2019;19:370.
    PubMed     Abstract available

  195. BRUNORO GVF, Carvalho PC, Barbosa VC, Pagnoncelli D, et al
    Differential proteomic comparison of breast cancer secretome using a quantitative paired analysis workflow.
    BMC Cancer. 2019;19:365.
    PubMed     Abstract available

  196. MCCLEMENTS L, Annett S, Yakkundi A, O'Rourke M, et al
    FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    BMC Cancer. 2019;19:351.
    PubMed     Abstract available

  197. GASS J, Mitchell S, Hanna M
    How do breast cancer surgery scars impact survivorship? Findings from a nationwide survey in the United States.
    BMC Cancer. 2019;19:342.
    PubMed     Abstract available

  198. ZHANG W, Jin ZQ, Baikpour M, Li JM, et al
    Clinical application of ultrasound-guided percutaneous microwave ablation for benign breast lesions: a prospective study.
    BMC Cancer. 2019;19:345.
    PubMed     Abstract available

  199. HEUSER C, Diekmann A, Kowalski C, Enders A, et al
    Health literacy and patient participation in multidisciplinary tumor conferences in breast cancer care: a multilevel modeling approach.
    BMC Cancer. 2019;19:330.
    PubMed     Abstract available

  200. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Horlings HM, et al
    A specific gene expression signature for visceral organ metastasis in breast cancer.
    BMC Cancer. 2019;19:333.
    PubMed     Abstract available

  201. WU L, Wu D, Ning J, Liu W, et al
    Changes of N6-methyladenosine modulators promote breast cancer progression.
    BMC Cancer. 2019;19:326.
    PubMed     Abstract available

  202. CAMPOY EM, Branham MT, Mayorga LS, Roque M, et al
    Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
    BMC Cancer. 2019;19:328.
    PubMed     Abstract available

  203. SHAHI RB, De Brakeleer S, Caljon B, Pauwels I, et al
    Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    BMC Cancer. 2019;19:313.
    PubMed     Abstract available

  204. FERRARO DA, Patella F, Zanivan S, Donato C, et al
    Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells.
    BMC Cancer. 2019;19:312.
    PubMed     Abstract available

  205. RAIHAN J, Ahmad U, Yong YK, Eshak Z, et al
    Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines.
    BMC Cancer. 2019;19:315.
    PubMed     Abstract available

  206. KLEIN J, Tran W, Watkins E, Vesprini D, et al
    Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis.
    BMC Cancer. 2019;19:306.
    PubMed     Abstract available

  207. CAMPBELL EJ, Dachs GU, Morrin HR, Davey VC, et al
    Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels.
    BMC Cancer. 2019;19:307.
    PubMed     Abstract available

  208. MULLAN PB, Bingham V, Haddock P, Irwin GW, et al
    NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.
    BMC Cancer. 2019;19:236.
    PubMed     Abstract available

    March 2019
  209. CAPERCHIONE CM, Sabiston CM, Stolp S, Bottorff JL, et al
    A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVE.
    BMC Cancer. 2019;19:272.
    PubMed     Abstract available

  210. MENDIETA I, Nunez-Anita RE, Nava-Villalba M, Zambrano-Estrada X, et al
    Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts.
    BMC Cancer. 2019;19:261.
    PubMed     Abstract available

  211. ABDULRASHID K, AlHussaini N, Ahmed W, Thalib L, et al
    Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.
    BMC Cancer. 2019;19:256.
    PubMed     Abstract available

  212. KIM MH, Kim DW, Park S, Kim JH, et al
    Single dose of dexamethasone is not associated with postoperative recurrence and mortality in breast cancer patients: a propensity-matched cohort study.
    BMC Cancer. 2019;19:251.
    PubMed     Abstract available

  213. ATTULURI AK, Serkad CPV, Gunda A, Ramkumar C, et al
    Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.
    BMC Cancer. 2019;19:249.
    PubMed     Abstract available

  214. SMELAND HY, Lu N, Karlsen TV, Salvesen G, et al
    Stromal integrin alpha11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors.
    BMC Cancer. 2019;19:234.
    PubMed     Abstract available

  215. YADAV S, Hartkop S, Cardenas PY, Ladkany R, et al
    Utilization of a breast cancer risk assessment tool by internal medicine residents in a primary care clinic: impact of an educational program.
    BMC Cancer. 2019;19:228.
    PubMed     Abstract available

  216. PHUNG MT, Tin Tin S, Elwood JM
    Prognostic models for breast cancer: a systematic review.
    BMC Cancer. 2019;19:230.
    PubMed     Abstract available

  217. RAMIREZ AB, Bhat R, Sahay D, De Angelis C, et al
    Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
    BMC Cancer. 2019;19:220.
    PubMed     Abstract available

  218. DE ALMEIDA BP, Apolonio JD, Binnie A, Castelo-Branco P, et al
    Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers.
    BMC Cancer. 2019;19:219.
    PubMed     Abstract available

  219. CHAI D, Li K, Du H, Yang S, et al
    beta2-microglobulin has a different regulatory molecular mechanism between ER(+) and ER(-) breast cancer with HER2().
    BMC Cancer. 2019;19:223.
    PubMed     Abstract available

  220. CHEN Q, Liu Y, Zhu XL, Feng F, et al
    Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo.
    BMC Cancer. 2019;19:211.
    PubMed     Abstract available

  221. XU Y, Kong S, Cheung WY, Bouchard-Fortier A, et al
    Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data.
    BMC Cancer. 2019;19:210.
    PubMed     Abstract available

  222. KUMAR N, Zhao D, Bhaumik D, Sethi A, et al
    Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
    BMC Cancer. 2019;19:215.
    PubMed     Abstract available

  223. MATOSSIAN MD, Burks HE, Elliott S, Hoang VT, et al
    Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    BMC Cancer. 2019;19:205.
    PubMed     Abstract available

  224. KATUWAL S, Tapanainen JS, Pukkala E, Kauppila A, et al
    The effect of length of birth interval on the risk of breast cancer by subtype in grand multiparous women.
    BMC Cancer. 2019;19:199.
    PubMed     Abstract available

  225. NARANG P, Chen M, Sharma AA, Anderson KS, et al
    The neoepitope landscape of breast cancer: implications for immunotherapy.
    BMC Cancer. 2019;19:200.
    PubMed     Abstract available

    February 2019
  226. DE LARA S, Nyqvist J, Werner Ronnerman E, Helou K, et al
    The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
    BMC Cancer. 2019;19:187.
    PubMed     Abstract available

  227. LIU H, Wang SH, Chen SC, Chen CY, et al
    Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
    BMC Cancer. 2019;19:176.
    PubMed     Abstract available

  228. LIU H, Chang X, Shang H, Li F, et al
    Diffuse cavernous hemangioma of the skull misdiagnosed as skull metastasis in breast cancer patient: one case report and literature review.
    BMC Cancer. 2019;19:172.
    PubMed     Abstract available

  229. RUIZ A, Sebagh M, Saffroy R, Allard MA, et al
    Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection.
    BMC Cancer. 2019;19:169.
    PubMed     Abstract available

  230. WOODHEAD C, Cunningham R, Ashworth M, Barley E, et al
    Correction to: Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study.
    BMC Cancer. 2019;19:152.
    PubMed     Abstract available

  231. KHAN OF, Cusano E, Raissouni S, Pabia M, et al
    Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study.
    BMC Cancer. 2019;19:150.
    PubMed     Abstract available

  232. PETITJEAN A, Smith-Palmer J, Valentine W, Tehard B, et al
    Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    BMC Cancer. 2019;19:140.
    PubMed     Abstract available

  233. AL-SALAM S, Sudhadevi M, Awwad A, Al Bashir M, et al
    Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy.
    BMC Cancer. 2019;19:135.
    PubMed     Abstract available

  234. WANG L, Liu L, Lou Z, Ding L, et al
    Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model.
    BMC Cancer. 2019;19:128.
    PubMed     Abstract available

  235. OGITA M, Sekiguchi K, Akahane K, Ito R, et al
    Damage to sebaceous gland and the efficacy of moisturizer after whole breast radiotherapy: a randomized controlled trial.
    BMC Cancer. 2019;19:125.
    PubMed     Abstract available

  236. KAHAN Z, Grecea D, Smakal M, Tjulandin S, et al
    Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    BMC Cancer. 2019;19:122.
    PubMed     Abstract available

  237. KONIG L, Mairinger FD, Hoffmann O, Bittner AK, et al
    Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
    BMC Cancer. 2019;19:120.
    PubMed     Abstract available

  238. GALLARDO-ALVARADO LN, Tusie-Luna MT, Tussie-Luna MI, Diaz-Chavez J, et al
    Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    BMC Cancer. 2019;19:118.
    PubMed     Abstract available

    January 2019
  239. DARLIX A, Hirtz C, Thezenas S, Maceski A, et al
    The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
    BMC Cancer. 2019;19:110.
    PubMed     Abstract available

  240. SCHAFFAR R, Belot A, Rachet B, Woods L, et al
    On the use of flexible excess hazard regression models for describing long-term breast cancer survival: a case-study using population-based cancer registry data.
    BMC Cancer. 2019;19:107.
    PubMed     Abstract available

  241. MUMIN NH, Drobnitzky N, Patel A, Lourenco LM, et al
    Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    BMC Cancer. 2019;19:102.
    PubMed     Abstract available

  242. SUAREZ-KELLY LP, Pasley WH, Clayton EJ, Povoski SP, et al
    Effect of topical microporous polysaccharide hemospheres on the duration and amount of fluid drainage following mastectomy: a prospective randomized clinical trial.
    BMC Cancer. 2019;19:99.
    PubMed     Abstract available

  243. ZHAO ZM, Yost SE, Hutchinson KE, Li SM, et al
    CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    BMC Cancer. 2019;19:96.
    PubMed     Abstract available

  244. KOTSAKIS A, Ardavanis A, Koumakis G, Samantas E, et al
    Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    BMC Cancer. 2019;19:88.
    PubMed     Abstract available

  245. EBNER F, Wockel A, Schwentner L, Blettner M, et al
    Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?
    BMC Cancer. 2019;19:90.
    PubMed     Abstract available

  246. MEERSON A, Eliraz Y, Yehuda H, Knight B, et al
    Obesity impacts the regulation of miR-10b and its targets in primary breast tumors.
    BMC Cancer. 2019;19:86.
    PubMed     Abstract available

  247. KIM HK, Lee SH, Kim YJ, Park SE, et al
    Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    BMC Cancer. 2019;19:84.
    PubMed     Abstract available

  248. MIAH S, Bagu E, Goel R, Ogunbolude Y, et al
    Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
    BMC Cancer. 2019;19:78.
    PubMed     Abstract available

  249. KANOMATA N, Kurebayashi J, Koike Y, Yamaguchi R, et al
    CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature.
    BMC Cancer. 2019;19:76.
    PubMed     Abstract available

  250. JEVRIC M, Matic IZ, Krivokuca A, Dordic Crnogorac M, et al
    Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    BMC Cancer. 2019;19:71.
    PubMed     Abstract available

  251. KIRKHAM AA, Ian Paterson D, Prado CM, Mackey JR, et al
    Correction to: Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2019;19:75.
    PubMed     Abstract available

  252. KHODABANDEHLOU N, Mostafaei S, Etemadi A, Ghasemi A, et al
    Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins.
    BMC Cancer. 2019;19:61.
    PubMed     Abstract available

  253. BORGQUIST S, Broberg P, Tojjar J, Olsson H, et al
    Statin use and breast cancer survival - a Swedish nationwide study.
    BMC Cancer. 2019;19:54.
    PubMed     Abstract available

  254. HOUVENAEGHEL G, Lambaudie E, Classe JM, Mazouni C, et al
    Lymph node positivity in different early breast carcinoma phenotypes: a predictive model.
    BMC Cancer. 2019;19:45.
    PubMed     Abstract available

  255. LOFTERS AK, McBride ML, Li D, Whitehead M, et al
    Disparities in breast cancer diagnosis for immigrant women in Ontario and BC: results from the CanIMPACT study.
    BMC Cancer. 2019;19:42.
    PubMed     Abstract available

  256. FRAMARINO-DEI-MALATESTA M, Chiarito A, Bianciardi F, Fiorelli M, et al
    Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
    BMC Cancer. 2019;19:36.
    PubMed     Abstract available

  257. MECHERA R, Soysal SD, Piscuoglio S, Ng CKY, et al
    Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
    BMC Cancer. 2019;19:41.
    PubMed     Abstract available

  258. SUN J, Wang X, Wang C
    Invasive cystic hypersecretory carcinoma of the breast: a rare variant of breast cancer: a case report and review of the literature.
    BMC Cancer. 2019;19:31.
    PubMed     Abstract available

  259. ZHU L, Chen K
    Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis.
    BMC Cancer. 2019;19:26.
    PubMed     Abstract available

  260. MASELLI-SCHOUERI JH, Affonso-Kaufman FA, de Melo Sette CV, Dos Santos Figueiredo FW, et al
    Time trend of breast cancer mortality in BRAZILIAN men: 10-year data analysis from 2005 to 2015.
    BMC Cancer. 2019;19:23.
    PubMed     Abstract available

  261. DE KRUIF JTCM, Visser M, van den Berg MMGA, Derks MJM, et al
    A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol.
    BMC Cancer. 2019;19:7.
    PubMed     Abstract available

  262. COTRIM DP, Ribeiro ARG, Paixao D, de Queiroz Soares DC, et al
    Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    BMC Cancer. 2019;19:4.
    PubMed     Abstract available

    December 2018
  263. HAMDI Y, Ben Rekaya M, Jingxuan S, Nagara M, et al
    A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci.
    BMC Cancer. 2018;18:1295.
    PubMed     Abstract available

  264. ZHAO J, Hu C, Wang C, Yu W, et al
    Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases.
    BMC Cancer. 2018;18:1290.
    PubMed     Abstract available

  265. TAKUWA H, Tsuji W, Shintaku M, Yotsumoto F, et al
    Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
    BMC Cancer. 2018;18:1282.
    PubMed     Abstract available

  266. SSEMMANDA S, Katagirya E, Bukirwa P, Alele D, et al
    Breast diseases histologically diagnosed at a tertiary facility in Uganda (2005-2014).
    BMC Cancer. 2018;18:1285.
    PubMed     Abstract available

  267. KUEHNEMUTH B, Piseddu I, Wiedemann GM, Lauseker M, et al
    CCL1 is a major regulatory T cell attracting factor in human breast cancer.
    BMC Cancer. 2018;18:1278.
    PubMed     Abstract available

  268. SCHMID R, Wolf K, Robering JW, Strauss S, et al
    ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
    BMC Cancer. 2018;18:1273.
    PubMed     Abstract available

  269. HICKS DG, Buscaglia B, Goda H, McMahon L, et al
    A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.
    BMC Cancer. 2018;18:1266.
    PubMed     Abstract available

  270. FORSARE C, Bak M, Falck AK, Grabau D, et al
    Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.
    BMC Cancer. 2018;18:1226.
    PubMed     Abstract available

  271. MOHAMMAD AS, Adkins CE, Shah N, Aljammal R, et al
    Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.
    BMC Cancer. 2018;18:1225.
    PubMed     Abstract available

  272. ANNUNZIATA MA, Muzzatti B, Bomben F, Flaiban C, et al
    A contribution to the validation of the Italian version of the Body Image Scale (BIS).
    BMC Cancer. 2018;18:1222.
    PubMed     Abstract available

  273. FARIAS AJ, Wu WH, Du XL
    Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    BMC Cancer. 2018;18:1214.
    PubMed     Abstract available

  274. LI TY, Chen VC, Yeh DC, Huang SL, et al
    Investigation of chemotherapy-induced brain structural alterations in breast cancer patients with generalized q-sampling MRI and graph theoretical analysis.
    BMC Cancer. 2018;18:1211.
    PubMed     Abstract available

    November 2018
  275. AL-QASSAB Y, Grassilli S, Brugnoli F, Vezzali F, et al
    Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.
    BMC Cancer. 2018;18:1194.
    PubMed     Abstract available

  276. RODRIGUEZ-VELAZQUEZ A, Velez R, Lafontaine JC, Colon-Echevarria CB, et al
    Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
    BMC Cancer. 2018;18:1177.
    PubMed     Abstract available

  277. CIFU G, Power MC, Shomstein S, Arem H, et al
    Mindfulness-based interventions and cognitive function among breast cancer survivors: a systematic review.
    BMC Cancer. 2018;18:1163.
    PubMed     Abstract available

  278. HOUVENAEGHEL G, Cohen M, Raro P, De Troyer J, et al
    Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
    BMC Cancer. 2018;18:1153.
    PubMed     Abstract available

  279. VAN OMMEN-NIJHOF A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, et al
    Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    BMC Cancer. 2018;18:1146.
    PubMed     Abstract available

  280. JIN B, Zhang S, Chuang X, Yu P, et al
    Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.
    BMC Cancer. 2018;18:1138.
    PubMed     Abstract available

  281. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer.
    BMC Cancer. 2018;18:1137.
    PubMed     Abstract available

  282. JEONG J, Seo K, Kim ES
    Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors.
    BMC Cancer. 2018;18:1109.
    PubMed     Abstract available

  283. YE FG, Xia C, Ma D, Lin PY, et al
    Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study.
    BMC Cancer. 2018;18:1085.
    PubMed     Abstract available

  284. DA COSTA AM, Hashim D, Fregnani JHTG, Weiderpass E, et al
    Overall survival and time trends in breast and cervical cancer incidence and mortality in the Regional Health District (RHD) of Barretos, Sao Paulo, Brazil.
    BMC Cancer. 2018;18:1079.
    PubMed     Abstract available

  285. OBERSTE M, Schaffrath N, Schmidt K, Bloch W, et al
    Protocol for the "Chemobrain in Motion - study" (CIM - study): a randomized placebo-controlled trial of the impact of a high-intensity interval endurance training on cancer related cognitive impairments in women with breast cancer receiving first-line
    BMC Cancer. 2018;18:1071.
    PubMed     Abstract available

  286. RINNERTHALER G, Gampenrieder SP, Petzer A, Burgstaller S, et al
    Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    BMC Cancer. 2018;18:1074.
    PubMed     Abstract available

  287. VAN DE WIEL HJ, Stuiver MM, May AM, van Grinsven S, et al
    (Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial.
    BMC Cancer. 2018;18:1073.
    PubMed     Abstract available

  288. LEE E, Luo J, Schumacher FR, Van Den Berg D, et al
    Growth factor genes and change in mammographic density after stopping combined hormone therapy in the California Teachers Study.
    BMC Cancer. 2018;18:1072.
    PubMed     Abstract available

    October 2018
  289. GASS P, Lux MP, Rauh C, Hein A, et al
    Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
    BMC Cancer. 2018;18:1051.
    PubMed     Abstract available

  290. LUHTALA S, Staff S, Kallioniemi A, Tanner M, et al
    Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    BMC Cancer. 2018;18:1045.
    PubMed     Abstract available

  291. CHEN L, Qi H, Zhang L, Li H, et al
    Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:1038.
    PubMed     Abstract available

  292. ARCINIEGAS CALLE MC, Sandhu NP, Xia H, Cha SS, et al
    Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    BMC Cancer. 2018;18:1037.
    PubMed     Abstract available

  293. JOHNSTON SJ, Ahmad D, Aleskandarany MA, Kurozumi S, et al
    Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.
    BMC Cancer. 2018;18:1027.
    PubMed     Abstract available

  294. VARGA K, Hollosi A, Paszty K, Hegedus L, et al
    Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
    BMC Cancer. 2018;18:1029.
    PubMed     Abstract available

  295. SARINK D, Schock H, Johnson T, Chang-Claude J, et al
    Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
    BMC Cancer. 2018;18:1010.
    PubMed     Abstract available

  296. SMITH YE, Toomey S, Napoletano S, Kirwan G, et al
    Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
    BMC Cancer. 2018;18:1016.
    PubMed     Abstract available

  297. DALMASSO B, Hatse S, Brouwers B, Laenen A, et al
    Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.
    BMC Cancer. 2018;18:1014.
    PubMed     Abstract available

  298. ZHAO Y, Lv F, Chen S, Wang Z, et al
    Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    BMC Cancer. 2018;18:1019.
    PubMed     Abstract available

  299. YANG Y, Cameron J, Bedi C, Humphris G, et al
    Fear of cancer recurrence trajectory during radiation treatment and follow-up into survivorship of patients with breast cancer.
    BMC Cancer. 2018;18:1002.
    PubMed     Abstract available

  300. GEERS J, Wildiers H, Van Calster K, Laenen A, et al
    Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer.
    BMC Cancer. 2018;18:994.
    PubMed     Abstract available

  301. REN JT, Wang MX, Su Y, Tang LY, et al
    Decelerated DNA methylation age predicts poor prognosis of breast cancer.
    BMC Cancer. 2018;18:989.
    PubMed     Abstract available

  302. ARAKI K, Ito Y, Fukada I, Kobayashi K, et al
    Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    BMC Cancer. 2018;18:982.
    PubMed     Abstract available

  303. DA SILVA BB, Eulalio Filho WMN, Costa PVL, Silva RA, et al
    A rare case of primary breast angiosarcoma in a male: a case report.
    BMC Cancer. 2018;18:978.
    PubMed     Abstract available

  304. LI L, Chang B, Jiang X, Fan X, et al
    Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
    BMC Cancer. 2018;18:977.
    PubMed     Abstract available

  305. EUSTACE AJ, Conlon NT, McDermott MSJ, Browne BC, et al
    Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    BMC Cancer. 2018;18:965.
    PubMed     Abstract available

  306. GHOREISHI Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, et al
    Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
    BMC Cancer. 2018;18:958.
    PubMed     Abstract available

  307. LEE KH, Kim EY, Yun JS, Park YL, et al
    The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
    BMC Cancer. 2018;18:938.
    PubMed     Abstract available

    September 2018
  308. INVERNIZZI M, Corti C, Lopez G, Michelotti A, et al
    Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up.
    BMC Cancer. 2018;18:935.
    PubMed     Abstract available

  309. LOPEZ-PINEDA A, Rodriguez-Moran MF, Alvarez-Aguilar C, Fuentes Valle SM, et al
    Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes.
    BMC Cancer. 2018;18:933.
    PubMed     Abstract available

  310. PELIZZARI G, Arpino G, Biganzoli L, Cinieri S, et al
    An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
    BMC Cancer. 2018;18:932.
    PubMed     Abstract available

  311. HOYER J, Vasileiou G, Uebe S, Wunderle M, et al
    Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    BMC Cancer. 2018;18:926.
    PubMed     Abstract available

  312. WANG RX, Chen S, Huang L, Shao ZM, et al
    Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
    BMC Cancer. 2018;18:909.
    PubMed     Abstract available

  313. JOUALI F, Marchoudi N, Talbi S, Bilal B, et al
    Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
    BMC Cancer. 2018;18:900.
    PubMed     Abstract available

  314. ELWOOD JM, Tawfiq E, TinTin S, Marshall RJ, et al
    Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.
    BMC Cancer. 2018;18:897.
    PubMed     Abstract available

  315. XIONG Z, Deng G, Wang J, Li X, et al
    Could local surgery improve survival in de novo stage IV breast cancer?
    BMC Cancer. 2018;18:885.
    PubMed     Abstract available

  316. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:876.
    PubMed     Abstract available

  317. SCHLIEMANN D, Donnelly M, Dahlui M, Loh SY, et al
    The 'Be Cancer Alert Campaign': protocol to evaluate a mass media campaign to raise awareness about breast and colorectal cancer in Malaysia.
    BMC Cancer. 2018;18:881.
    PubMed     Abstract available

  318. SOBOTA A, Ozakinci G
    Determinants of fertility issues experienced by young women diagnosed with breast or gynaecological cancer - a quantitative, cross-cultural study.
    BMC Cancer. 2018;18:874.
    PubMed     Abstract available

  319. KALINKOVA L, Zmetakova I, Smolkova B, Minarik G, et al
    Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.
    BMC Cancer. 2018;18:875.
    PubMed     Abstract available

  320. FAJKA-BOJA R, Marton A, Toth A, Blazso P, et al
    Increased insulin-like growth factor 1 production by polyploid adipose stem cells promotes growth of breast cancer cells.
    BMC Cancer. 2018;18:872.
    PubMed     Abstract available

  321. KIRKHAM AA, Paterson DI, Prado CM, Mackey JM, et al
    Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2018;18:864.
    PubMed     Abstract available

  322. DUIVON M, Perrier J, Joly F, Licaj I, et al
    Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study.
    BMC Cancer. 2018;18:866.
    PubMed     Abstract available

  323. NIAZI MKK, Senaras C, Pennell M, Arole V, et al
    Relationship between the Ki67 index and its area based approximation in breast cancer.
    BMC Cancer. 2018;18:867.
    PubMed     Abstract available

  324. BROEDERS MJM, Allgood P, Duffy SW, Hofvind S, et al
    The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.
    BMC Cancer. 2018;18:860.
    PubMed     Abstract available

    August 2018
  325. HEIL J, Sinn P, Richter H, Pfob A, et al
    RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
    BMC Cancer. 2018;18:851.
    PubMed     Abstract available

  326. HULTSCH S, Kankainen M, Paavolainen L, Kovanen RM, et al
    Association of tamoxifen resistance and lipid reprogramming in breast cancer.
    BMC Cancer. 2018;18:850.
    PubMed     Abstract available

  327. FUMET JD, Wickre M, Jacquot JP, Bizollon MH, et al
    Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
    BMC Cancer. 2018;18:839.
    PubMed     Abstract available

  328. FISH EJ, Irizarry KJ, DeInnocentes P, Ellis CJ, et al
    Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks.
    BMC Cancer. 2018;18:832.
    PubMed     Abstract available

  329. MENG M, Xue H, Lei J, Wang Q, et al
    A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis.
    BMC Cancer. 2018;18:833.
    PubMed     Abstract available

  330. VAN BASTELAAR J, Granzier R, van Roozendaal LM, Beets G, et al
    A multi-center, double blind randomized controlled trial evaluating flap fixation after mastectomy using sutures or tissue glue versus conventional closure: protocol for the Seroma reduction After Mastectomy (SAM) trial.
    BMC Cancer. 2018;18:830.
    PubMed     Abstract available

  331. MENG LL, Wang JL, Xu SP, Zu LD, et al
    Low serum gastrin associated with ER(+) breast cancer development via inactivation of CCKBR/ERK/P65 signaling.
    BMC Cancer. 2018;18:824.
    PubMed     Abstract available

  332. RICHTER-EHRENSTEIN C, Maak K, Roger S, Ehrenstein T, et al
    Lesions of "uncertain malignant potential" in the breast (B3) identified with mammography screening.
    BMC Cancer. 2018;18:829.
    PubMed     Abstract available

  333. WANG B, Li D, Rodriguez-Juarez R, Farfus A, et al
    A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    BMC Cancer. 2018;18:817.
    PubMed     Abstract available

  334. DENARD B, Jiang S, Peng Y, Ye J, et al
    CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
    BMC Cancer. 2018;18:813.
    PubMed     Abstract available

  335. AIDERUS A, Black MA, Dunbier AK
    Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.
    BMC Cancer. 2018;18:805.
    PubMed     Abstract available

  336. AXELSSON U, Ryden L, Johnsson P, Eden P, et al
    A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study.
    BMC Cancer. 2018;18:789.
    PubMed     Abstract available

  337. BAEYENS-FERNANDEZ JA, Molina-Portillo E, Pollan M, Rodriguez-Barranco M, et al
    Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study.
    BMC Cancer. 2018;18:781.
    PubMed     Abstract available

    July 2018
  338. VIALA M, Chiba A, Thezenas S, Delmond L, et al
    Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.
    BMC Cancer. 2018;18:770.
    PubMed     Abstract available

  339. BEELEN K, Opdam M, Severson T, Koornstra R, et al
    Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
    BMC Cancer. 2018;18:761.
    PubMed     Abstract available

  340. LEE M, Tayyari F, Pinnaduwage D, Bayani J, et al
    Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
    BMC Cancer. 2018;18:750.
    PubMed     Abstract available

  341. GIBBONS JA, Kanwar JR, Kanwar RK
    Correction to: Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer.
    BMC Cancer. 2018;18:749.
    PubMed     Abstract available

  342. RETHORST CD, Hamann HA, Carmody TJ, Sharp KJ, et al
    The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors.
    BMC Cancer. 2018;18:744.
    PubMed     Abstract available

  343. VASMATZIS G, Wang X, Smadbeck JB, Murphy SJ, et al
    Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2(+) breast cancer samples.
    BMC Cancer. 2018;18:738.
    PubMed     Abstract available

  344. LAMBERT LK, Balneaves LG, Howard AF, Chia SK, et al
    Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    BMC Cancer. 2018;18:732.
    PubMed     Abstract available

  345. NUSHTAEVA AA, Stepanov GA, Semenov DV, Juravlev ES, et al
    Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents.
    BMC Cancer. 2018;18:728.
    PubMed     Abstract available

  346. HE Y, Tan EH, Wong ALA, Tan CC, et al
    Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
    BMC Cancer. 2018;18:727.
    PubMed     Abstract available

  347. YOON YN, Choe MH, Jung KY, Hwang SG, et al
    MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
    BMC Cancer. 2018;18:716.
    PubMed     Abstract available

  348. SLAOUI M, Zoure AA, Mouh FZ, Bensouda Y, et al
    Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
    BMC Cancer. 2018;18:713.
    PubMed     Abstract available

  349. REAL SAS, Parveen F, Rehman AU, Khan MA, et al
    Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients.
    BMC Cancer. 2018;18:711.
    PubMed     Abstract available

  350. RANGEL N, Fortunati N, Osella-Abate S, Annaratone L, et al
    FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    BMC Cancer. 2018;18:703.
    PubMed     Abstract available

    June 2018
  351. ZOPPINO FCM, Guerrero-Gimenez ME, Castro GN, Ciocca DR, et al
    Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer.
    BMC Cancer. 2018;18:700.
    PubMed     Abstract available

  352. HAYASHIDA T, Jinno H, Mori K, Sato H, et al
    Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    BMC Cancer. 2018;18:701.
    PubMed     Abstract available

  353. VAN GELDERMALSEN M, Quek LE, Turner N, Freidman N, et al
    Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.
    BMC Cancer. 2018;18:689.
    PubMed     Abstract available

  354. EHLERS DK, Fanning J, Salerno EA, Aguinaga S, et al
    Replacing sedentary time with physical activity or sleep: effects on cancer-related cognitive impairment in breast cancer survivors.
    BMC Cancer. 2018;18:685.
    PubMed     Abstract available

  355. GREGOIRE C, Nicolas H, Bragard I, Delevallez F, et al
    Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients.
    BMC Cancer. 2018;18:677.
    PubMed     Abstract available

  356. INOUE K, Ninomiya J, Saito T, Kimizuka K, et al
    Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 3
    BMC Cancer. 2018;18:671.
    PubMed     Abstract available

  357. LI Y, Du Y, Sun T, Xue H, et al
    PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
    BMC Cancer. 2018;18:669.
    PubMed     Abstract available

  358. LI R, Xiao C, Liu H, Huang Y, et al
    Effects of local anesthetics on breast cancer cell viability and migration.
    BMC Cancer. 2018;18:666.
    PubMed     Abstract available

  359. XU H, Xu Y, Ouyang T, Li J, et al
    Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
    BMC Cancer. 2018;18:662.
    PubMed     Abstract available

  360. LOFTEROD T, Mortensen ES, Nalwoga H, Wilsgaard T, et al
    Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.
    BMC Cancer. 2018;18:654.
    PubMed     Abstract available

  361. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:651.
    PubMed     Abstract available

  362. DUSENGIMANA JMV, Hategekimana V, Borg R, Hedt-Gauthier B, et al
    Pregnancy-associated breast cancer in rural Rwanda: the experience of the Butaro Cancer Center of Excellence.
    BMC Cancer. 2018;18:634.
    PubMed     Abstract available

    May 2018
  363. NATTENMULLER CJ, Kriegsmann M, Sookthai D, Fortner RT, et al
    Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study.
    BMC Cancer. 2018;18:616.
    PubMed     Abstract available

  364. WHITNEY J, Corredor G, Janowczyk A, Ganesan S, et al
    Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
    BMC Cancer. 2018;18:610.
    PubMed     Abstract available

  365. MADHU KRISHNA B, Chaudhary S, Mishra DR, Naik SK, et al
    Estrogen receptor alpha dependent regulation of estrogen related receptor beta and its role in cell cycle in breast cancer.
    BMC Cancer. 2018;18:607.
    PubMed     Abstract available

  366. HOUSE CD, Grajales V, Ozaki M, Jordan E, et al
    IKappaKappaepsilon cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
    BMC Cancer. 2018;18:595.
    PubMed     Abstract available

  367. MUDDUWA L, Peiris H, Gunasekara S, Abeysiriwardhana D, et al
    KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.
    BMC Cancer. 2018;18:589.
    PubMed     Abstract available

  368. FORTE L, Turdo F, Ghirelli C, Aiello P, et al
    The PDGFRbeta/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
    BMC Cancer. 2018;18:586.
    PubMed     Abstract available

  369. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Abstract available

  370. PARASHAR S, Cheishvili D, Mahmood N, Arakelian A, et al
    DNA methylation signatures of breast cancer in peripheral T-cells.
    BMC Cancer. 2018;18:574.
    PubMed     Abstract available

  371. BATES JP, Derakhshandeh R, Jones L, Webb TJ, et al
    Mechanisms of immune evasion in breast cancer.
    BMC Cancer. 2018;18:556.
    PubMed     Abstract available

  372. BANYS-PALUCHOWSKI M, Fehm T, Janni W, Aktas B, et al
    Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    BMC Cancer. 2018;18:541.
    PubMed     Abstract available

  373. SHULDINER J, Liu Y, Lofters A
    Incidence of breast and colorectal cancer among immigrants in Ontario, Canada: a retrospective cohort study from 2004-2014.
    BMC Cancer. 2018;18:537.
    PubMed     Abstract available

  374. DOUGAN MM, Li Y, Chu LW, Haile RW, et al
    Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry.
    BMC Cancer. 2018;18:532.
    PubMed     Abstract available

  375. NAIK A, Al-Yahyaee A, Abdullah N, Sam JE, et al
    Neuropilin-1 promotes the oncogenic Tenascin-C/integrin beta3 pathway and modulates chemoresistance in breast cancer cells.
    BMC Cancer. 2018;18:533.
    PubMed     Abstract available

  376. PENAULT-LLORCA F, Filleron T, Asselain B, Baehner FL, et al
    The 21-gene Recurrence Score(R) assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 tria
    BMC Cancer. 2018;18:526.
    PubMed     Abstract available

  377. LI W, Xu L, Che X, Li H, et al
    C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    BMC Cancer. 2018;18:507.
    PubMed     Abstract available

  378. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Abstract available

    April 2018
  379. HUANG S, Murphy L, Xu W
    Genes and functions from breast cancer signatures.
    BMC Cancer. 2018;18:473.
    PubMed     Abstract available

  380. FERNANDO A, Jayarajah U, Prabashani S, Fernando EA, et al
    Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database.
    BMC Cancer. 2018;18:482.
    PubMed     Abstract available

  381. BAUERSFELD SP, Kessler CS, Wischnewsky M, Jaensch A, et al
    The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
    BMC Cancer. 2018;18:476.
    PubMed     Abstract available

  382. DOGAN A, Kern P, Schultheis B, Hausler G, et al
    Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
    BMC Cancer. 2018;18:463.
    PubMed     Abstract available

  383. CATSMAN CJLM, Beek MA, Voogd AC, Mulder PGH, et al
    The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery.
    BMC Cancer. 2018;18:456.
    PubMed     Abstract available

  384. LIUTKAUSKIENE S, Grizas S, Jureniene K, Suipyte J, et al
    Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
    BMC Cancer. 2018;18:453.
    PubMed     Abstract available

  385. PODRALSKA M, Ziolkowska-Suchanek I, Zurawek M, Dzikiewicz-Krawczyk A, et al
    Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.
    BMC Cancer. 2018;18:452.
    PubMed     Abstract available

  386. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Abstract available

  387. SEMMLINGER A, von Schoenfeldt V, Wolf V, Meuter A, et al
    EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
    BMC Cancer. 2018;18:431.
    PubMed     Abstract available

  388. XIAO B, Chen L, Ke Y, Hang J, et al
    Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
    BMC Cancer. 2018;18:405.
    PubMed     Abstract available

  389. DEFOSSEZ G, Quillet A, Ingrand P
    Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.
    BMC Cancer. 2018;18:393.
    PubMed     Abstract available

  390. HILLER L, Dunn JA, Loi S, Vallier AL, et al
    Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
    BMC Cancer. 2018;18:391.
    PubMed     Abstract available

  391. VAN DER WAAL D, Verbeek ALM, Broeders MJM
    Breast density and breast cancer-specific survival by detection mode.
    BMC Cancer. 2018;18:386.
    PubMed     Abstract available

  392. BALEKOUZOU A, Yin P, Bekolo CE, Pamatika CM, et al
    Histo-epidemiological profile of breast cancers among women in the Central African Republic: about 174 cases.
    BMC Cancer. 2018;18:387.
    PubMed     Abstract available

  393. PHI XA, Tagliafico A, Houssami N, Greuter MJW, et al
    Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis.
    BMC Cancer. 2018;18:380.
    PubMed     Abstract available

  394. HUNG CH, Chen FM, Lin YC, Tsai ML, et al
    Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer.
    BMC Cancer. 2018;18:366.
    PubMed     Abstract available

  395. LIU Y, Du Y, Hu X, Zhao L, et al
    Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer.
    BMC Cancer. 2018;18:367.
    PubMed     Abstract available

    March 2018
  396. AN X, Xu F, Luo R, Zheng Q, et al
    The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
    BMC Cancer. 2018;18:331.
    PubMed     Abstract available

  397. CHEN J, Zhu Y, Zhang W, Peng X, et al
    Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells.
    BMC Cancer. 2018;18:342.
    PubMed     Abstract available

  398. DITTUS KL, Harvey JR, Bunn JY, Kokinda ND, et al
    Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors.
    BMC Cancer. 2018;18:351.
    PubMed     Abstract available

  399. BRONTE G, Rocca A, Ravaioli S, Puccetti M, et al
    Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    BMC Cancer. 2018;18:348.
    PubMed     Abstract available

  400. XU Y, Yang X, Wang T, Yang L, et al
    Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-gamma-linolenic acid peroxidation dependent mechanism.
    BMC Cancer. 2018;18:330.
    PubMed     Abstract available

  401. SALIMI M, Wang R, Yao X, Li X, et al
    Activated innate lymphoid cell populations accumulate in human tumour tissues.
    BMC Cancer. 2018;18:341.
    PubMed     Abstract available

  402. MARMARA D, Marmara V, Hubbard G
    A national cross-sectional study of adherence to timely mammography use in Malta.
    BMC Cancer. 2018;18:346.
    PubMed     Abstract available

  403. AHN SG, Cha YJ, Bae SJ, Yoon C, et al
    Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    BMC Cancer. 2018;18:320.
    PubMed     Abstract available

  404. WANG YA, Jian JW, Hung CF, Peng HP, et al
    Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    BMC Cancer. 2018;18:315.
    PubMed     Abstract available

  405. MOODLEY J, Cairncross L, Naiker T, Constant D, et al
    From symptom discovery to treatment - women's pathways to breast cancer care: a cross-sectional study.
    BMC Cancer. 2018;18:312.
    PubMed     Abstract available

  406. ZHANG JJ, Shu H, Hu SS, Yu Y, et al
    Relationship between time elapsed since completion of radiotherapy and quality of life of patients with breast cancer.
    BMC Cancer. 2018;18:305.
    PubMed     Abstract available

  407. MENSAH KB, Oosthuizen F, Bonsu AB
    Cancer awareness among community pharmacist: a systematic review.
    BMC Cancer. 2018;18:299.
    PubMed     Abstract available

  408. MULLER V, Clemens M, Jassem J, Al-Sakaff N, et al
    Long-term trastuzumab (Herceptin(R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    BMC Cancer. 2018;18:295.
    PubMed     Abstract available

  409. HARDI H, Melki R, Boughaleb Z, El Harroudi T, et al
    Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    BMC Cancer. 2018;18:292.
    PubMed     Abstract available

  410. MCANENA PF, McGuire A, Ramli A, Curran C, et al
    Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:282.
    PubMed     Abstract available

  411. DAVID D, Surendran A, Thulaseedharan JV, Nair AS, et al
    Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.
    BMC Cancer. 2018;18:284.
    PubMed     Abstract available

  412. DIERSSEN-SOTOS T, Palazuelos-Calderon C, Jimenez-Moleon JJ, Aragones N, et al
    Reproductive risk factors in breast cancer and genetic hormonal pathways: a gene-environment interaction in the MCC-Spain project.
    BMC Cancer. 2018;18:280.
    PubMed     Abstract available

  413. SONG Q, Chen Q, Wang Q, Yang L, et al
    ATF-3/miR-590/GOLPH3 signaling pathway regulates proliferation of breast cancer.
    BMC Cancer. 2018;18:255.
    PubMed     Abstract available

  414. NAAB TJ, Gautam A, Ricks-Santi L, Esnakula AK, et al
    MYC amplification in subtypes of breast cancers in African American women.
    BMC Cancer. 2018;18:274.
    PubMed     Abstract available

  415. YANG L, Wang J, Cheng J, Wang Y, et al
    Quality assurance target for community-based breast cancer screening in China: a model simulation.
    BMC Cancer. 2018;18:261.
    PubMed     Abstract available

  416. VONDELING GT, Menezes GL, Dvortsin EP, Jansman FGA, et al
    Burden of early, advanced and metastatic breast cancer in The Netherlands.
    BMC Cancer. 2018;18:262.
    PubMed     Abstract available

  417. ENGEL C, Rhiem K, Hahnen E, Loibl S, et al
    Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    BMC Cancer. 2018;18:265.
    PubMed     Abstract available

  418. ANWAR SL, Tampubolon G, Van Hemelrijck M, Hutajulu SH, et al
    Determinants of cancer screening awareness and participation among Indonesian women.
    BMC Cancer. 2018;18:208.
    PubMed     Abstract available

  419. SANKATSING VDV, Fracheboud J, de Munck L, Broeders MJM, et al
    Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.
    BMC Cancer. 2018;18:256.
    PubMed     Abstract available

    February 2018
  420. ISFOSS BL, Holmqvist B, Sand E, Forsell J, et al
    Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study.
    BMC Cancer. 2018;18:230.
    PubMed     Abstract available

  421. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Abstract available

  422. GAVA F, Rigal L, Mondesert O, Pesce E, et al
    Gap junctions contribute to anchorage-independent clustering of breast cancer cells.
    BMC Cancer. 2018;18:221.
    PubMed     Abstract available

  423. JAASKELAINEN A, Soini Y, Jukkola-Vuorinen A, Auvinen P, et al
    High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
    BMC Cancer. 2018;18:223.
    PubMed     Abstract available

  424. BRONSVELD HK, De Bruin ML, Wesseling J, Sanders J, et al
    The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
    BMC Cancer. 2018;18:224.
    PubMed     Abstract available

  425. HOU MF, Chen PM, Chu PY
    LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
    BMC Cancer. 2018;18:219.
    PubMed     Abstract available

  426. MCANENA PF, Brown JA, Ramli A, Curran C, et al
    Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:203.
    PubMed     Abstract available

  427. HUEBNER H, Fasching PA, Gumbrecht W, Jud S, et al
    Filtration based assessment of CTCs and CellSearch(R) based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    BMC Cancer. 2018;18:204.
    PubMed     Abstract available

  428. WESTVIK AS, Weedon-Fekjaer H, Maehlen J, Liestol K, et al
    Evaluating different breast tumor progression models using screening data.
    BMC Cancer. 2018;18:209.
    PubMed     Abstract available

  429. SIRISENA ND, Adeyemo A, Kuruppu AI, Neththikumara N, et al
    Genetic determinants of sporadic breast cancer in Sri Lankan women.
    BMC Cancer. 2018;18:180.
    PubMed     Abstract available

  430. NOJIMA M, Iwasaki M, Kasuga Y, Yokoyama S, et al
    Correlation between global methylation level of peripheral blood leukocytes and serum C reactive protein level modified by MTHFR polymorphism: a cross-sectional study.
    BMC Cancer. 2018;18:184.
    PubMed     Abstract available

  431. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Abstract available

  432. IBRAHIM M, Yadav S, Ogunleye F, Zakalik D, et al
    Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    BMC Cancer. 2018;18:179.
    PubMed     Abstract available

  433. KJALLQUIST U, Erlandsson R, Tobin NP, Alkodsi A, et al
    Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).
    BMC Cancer. 2018;18:174.
    PubMed     Abstract available

  434. AL DOSSARY R, Alkharsah KR, Kussaibi H
    Prevalence of Mouse Mammary Tumor Virus (MMTV)-like sequences in human breast cancer tissues and adjacent normal breast tissues in Saudi Arabia.
    BMC Cancer. 2018;18:170.
    PubMed     Abstract available

  435. LAFOURCADE A, His M, Baglietto L, Boutron-Ruault MC, et al
    Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort.
    BMC Cancer. 2018;18:171.
    PubMed     Abstract available

  436. NGUYEN-DUMONT T, Teo ZL, Hammet F, Roberge A, et al
    Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?
    BMC Cancer. 2018;18:165.
    PubMed     Abstract available

  437. CORTET M, Bertaut A, Molinie F, Bara S, et al
    Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries.
    BMC Cancer. 2018;18:161.
    PubMed     Abstract available

  438. LAM WWT, Kwong A, Suen D, Tsang J, et al
    Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study.
    BMC Cancer. 2018;18:162.
    PubMed     Abstract available

  439. LIM JA, Oh CS, Yoon TG, Lee JY, et al
    The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis.
    BMC Cancer. 2018;18:159.
    PubMed     Abstract available

  440. ABDEL-RAZEQ H, Al-Omari A, Zahran F, Arun B, et al
    Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan.
    BMC Cancer. 2018;18:152.
    PubMed     Abstract available

  441. PENSABENE M, Stanzione B, Cerillo I, Ciancia G, et al
    It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.
    BMC Cancer. 2018;18:146.
    PubMed     Abstract available

  442. ALUNNI-FABBRONI M, Majunke L, Trapp EK, Tzschaschel M, et al
    Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    BMC Cancer. 2018;18:141.
    PubMed     Abstract available

  443. TRAORE BM, El Fakir S, Charaka H, Benaicha N, et al
    Evolution of quality of life in patients with breast cancer during the first year of follow-up in Morocco.
    BMC Cancer. 2018;18:109.
    PubMed     Abstract available

  444. NOVAK J, Besic N, Dzodic R, Gazic B, et al
    Pre-operative and intra-operative detection of axillary lymph node metastases in 108 patients with invasive lobular breast cancer undergoing mastectomy.
    BMC Cancer. 2018;18:137.
    PubMed     Abstract available

  445. BEGUINOT M, Dauplat MM, Kwiatkowski F, Lebouedec G, et al
    Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    BMC Cancer. 2018;18:129.
    PubMed     Abstract available

  446. KAEWKANGSADAN V, Verma C, Eremin JM, Cowley G, et al
    Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumo
    BMC Cancer. 2018;18:123.
    PubMed     Abstract available

    January 2018
  447. EVANS RL, Pottala JV, Nagata S, Egland KA, et al
    Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.
    BMC Cancer. 2018;18:119.
    PubMed     Abstract available

  448. HSIEH E, Wang Q, Zhang R, Niu X, et al
    Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps.
    BMC Cancer. 2018;18:104.
    PubMed     Abstract available

  449. FRERES P, Bouznad N, Servais L, Josse C, et al
    Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:102.
    PubMed     Abstract available

  450. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Abstract available

  451. HAQUE I, Ghosh A, Acup S, Banerjee S, et al
    Leptin-induced ER-alpha-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.
    BMC Cancer. 2018;18:99.
    PubMed     Abstract available

  452. DE LIGT KM, Witteveen A, Siesling S, Steuten LMG, et al
    Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study.
    BMC Cancer. 2018;18:96.
    PubMed     Abstract available

  453. PARK VY, Kim EK, Kim MJ, Moon HJ, et al
    Breast magnetic resonance imaging for surveillance of women with a personal history of breast cancer: outcomes stratified by interval between definitive surgery and surveillance MR imaging.
    BMC Cancer. 2018;18:91.
    PubMed     Abstract available

  454. PARK JS, Lee ST, Nam EJ, Han JW, et al
    Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    BMC Cancer. 2018;18:83.
    PubMed     Abstract available

  455. ELWOOD JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, et al
    Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study.
    BMC Cancer. 2018;18:76.
    PubMed     Abstract available

  456. BERNAL-ESTEVEZ DA, Garcia O, Sanchez R, Parra-Lopez CA, et al
    Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy.
    BMC Cancer. 2018;18:77.
    PubMed     Abstract available

  457. YU SJ, Yang L, Hong Q, Kuang XY, et al
    MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
    BMC Cancer. 2018;18:74.
    PubMed     Abstract available

  458. GARCIA-GUTIERREZ S, Orive M, Sarasqueta C, Legarreta MJ, et al
    Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study.
    BMC Cancer. 2018;18:54.
    PubMed     Abstract available

  459. DALL P, Koch T, Gohler T, Selbach J, et al
    Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study.
    BMC Cancer. 2018;18:51.
    PubMed     Abstract available

  460. TIN TIN S, Elwood JM, Brown C, Sarfati D, et al
    Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?
    BMC Cancer. 2018;18:58.
    PubMed     Abstract available

  461. URRU SAM, Gallus S, Bosetti C, Moi T, et al
    Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    BMC Cancer. 2018;18:56.
    PubMed     Abstract available

  462. KUMAR D, Haldar S, Gorain M, Kumar S, et al
    Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway.
    BMC Cancer. 2018;18:52.
    PubMed     Abstract available

  463. LOVITT CJ, Shelper TB, Avery VM
    Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins.
    BMC Cancer. 2018;18:41.
    PubMed     Abstract available

  464. PARK E, Yoon J, Choi EK, Kim IR, et al
    A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors.
    BMC Cancer. 2018;18:45.
    PubMed     Abstract available

  465. LOUHICHI T, Saad H, Dhiab MB, Ziadi S, et al
    Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype.
    BMC Cancer. 2018;18:49.
    PubMed     Abstract available

  466. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Abstract available

  467. NZEANGUNG BA, Biwole ME, Kadia BM, Bechem NN, et al
    Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon.
    BMC Cancer. 2018;18:32.
    PubMed     Abstract available

  468. NARRANDES S, Huang S, Murphy L, Xu W, et al
    The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    BMC Cancer. 2018;18:22.
    PubMed     Abstract available

  469. ZHOU K, He X, Huo L, An J, et al
    Development of the body image self-rating questionnaire for breast cancer (BISQ-BC) for Chinese mainland patients.
    BMC Cancer. 2018;18:19.
    PubMed     Abstract available

  470. PATRICIO M, Pereira J, Crisostomo J, Matafome P, et al
    Using Resistin, glucose, age and BMI to predict the presence of breast cancer.
    BMC Cancer. 2018;18:29.
    PubMed     Abstract available

  471. LI M, Li A, Zhou S, Xu Y, et al
    Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    BMC Cancer. 2018;18:4.
    PubMed     Abstract available

    December 2017
  472. LYNGE E, Bak M, von Euler-Chelpin M, Kroman N, et al
    Outcome of breast cancer screening in Denmark.
    BMC Cancer. 2017;17:897.
    PubMed     Abstract available

  473. HUANG LH, Chung HY, Su HM
    Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
    BMC Cancer. 2017;17:890.
    PubMed     Abstract available

  474. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    BMC Cancer. 2017;17:888.
    PubMed     Abstract available

  475. MERCOGLIANO MF, Inurrigarro G, De Martino M, Venturutti L, et al
    Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
    BMC Cancer. 2017;17:895.
    PubMed     Abstract available

  476. LIU LN, Lin YC, Miaskowski C, Chen SC, et al
    Association between changes in body fat and disease progression after breast cancer surgery is moderated by menopausal status.
    BMC Cancer. 2017;17:863.
    PubMed     Abstract available

  477. KRISHNAN K, Baglietto L, Stone J, McLean C, et al
    Mammographic density and risk of breast cancer by tumor characteristics: a case-control study.
    BMC Cancer. 2017;17:859.
    PubMed     Abstract available

  478. KUMARI K, Keshari S, Sengupta D, Sabat SC, et al
    Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.
    BMC Cancer. 2017;17:858.
    PubMed     Abstract available

  479. WU Y, Zhang N, Yang Q
    The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.
    BMC Cancer. 2017;17:839.
    PubMed     Abstract available

  480. GAO D, Cazares LH, Fish EN
    CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.
    BMC Cancer. 2017;17:834.
    PubMed     Abstract available

  481. BAXTER GD, Liu L, Petrich S, Gisselman AS, et al
    Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review.
    BMC Cancer. 2017;17:833.
    PubMed     Abstract available

  482. PHAM TND, Perez White BE, Zhao H, Mortazavi F, et al
    Protein kinase C alpha enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.
    BMC Cancer. 2017;17:832.
    PubMed     Abstract available

  483. KO H, Shin J, Lee JE, Nam SJ, et al
    Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.
    BMC Cancer. 2017;17:821.
    PubMed     Abstract available

  484. OCHNIK AM, Baxter RC
    Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer.
    BMC Cancer. 2017;17:820.
    PubMed     Abstract available

  485. HE D, Fang Y, Gunter MJ, Xu D, et al
    Incidence of breast cancer in Chinese women exposed to the 1959-1961 great Chinese famine.
    BMC Cancer. 2017;17:824.
    PubMed     Abstract available

  486. IIZUMI S, Shimoi T, Tsushita N, Bun S, et al
    Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    BMC Cancer. 2017;17:819.
    PubMed     Abstract available

  487. THOMAS ET, Del Mar C, Glasziou P, Wright G, et al
    Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis.
    BMC Cancer. 2017;17:808.
    PubMed     Abstract available

  488. SENGAL AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, et al
    Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    BMC Cancer. 2017;17:804.
    PubMed     Abstract available

    November 2017
  489. KARTHIK GM, Rantalainen M, Stalhammar G, Lovrot J, et al
    Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.
    BMC Cancer. 2017;17:802.
    PubMed     Abstract available

  490. QATTAN A, Intabli H, Alkhayal W, Eltabache C, et al
    Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    BMC Cancer. 2017;17:799.
    PubMed     Abstract available

  491. GIORDANO L, Gallo F, Petracci E, Chiorino G, et al
    The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol.
    BMC Cancer. 2017;17:785.
    PubMed     Abstract available

  492. TAKESHITA T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, et al
    Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
    BMC Cancer. 2017;17:786.
    PubMed     Abstract available

  493. WONG XY, Chong KJ, van Til JA, Wee HL, et al
    A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    BMC Cancer. 2017;17:776.
    PubMed     Abstract available

  494. SHIROIWA T, Fukuda T, Shimozuma K, Mouri M, et al
    Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    BMC Cancer. 2017;17:773.
    PubMed     Abstract available

  495. ISAKOVA J, Talaibekova E, Aldasheva N, Vinnikov D, et al
    The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
    BMC Cancer. 2017;17:758.
    PubMed     Abstract available

  496. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Van de Vijver MJ, et al
    Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
    BMC Cancer. 2017;17:755.
    PubMed     Abstract available

  497. LI J, Lai Y, Ma J, Liu Y, et al
    miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    BMC Cancer. 2017;17:745.
    PubMed     Abstract available

  498. KHAN UT, Walker AJ, Baig S, Card TR, et al
    Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.
    BMC Cancer. 2017;17:747.
    PubMed     Abstract available

  499. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Abstract available

  500. MINICHILLO S, Gallelli I, Barbieri E, Cubelli M, et al
    Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
    BMC Cancer. 2017;17:722.
    PubMed     Abstract available

  501. QUINTERO M, Adamoski D, Reis LMD, Ascencao CFR, et al
    Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
    BMC Cancer. 2017;17:727.
    PubMed     Abstract available

  502. GOHR K, Hamacher A, Engelke LH, Kassack MU, et al
    Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC Cancer. 2017;17:711.
    PubMed     Abstract available

  503. LANZ HL, Saleh A, Kramer B, Cairns J, et al
    Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    BMC Cancer. 2017;17:709.
    PubMed     Abstract available

    October 2017
  504. REPO H, Gurvits N, Loyttyniemi E, Nykanen M, et al
    PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.
    BMC Cancer. 2017;17:705.
    PubMed     Abstract available

  505. D'ALOISIO AA, Nichols HB, Hodgson ME, Deming-Halverson SL, et al
    Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.
    BMC Cancer. 2017;17:692.
    PubMed     Abstract available

  506. KIM HM, Lee J, Koo JS
    Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    BMC Cancer. 2017;17:690.
    PubMed     Abstract available

  507. JAHN B, Rochau U, Kurzthaler C, Hubalek M, et al
    Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
    BMC Cancer. 2017;17:685.
    PubMed     Abstract available

  508. LYSZCZARZ B, Nojszewska E
    Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014.
    BMC Cancer. 2017;17:676.
    PubMed     Abstract available

    September 2017
  509. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Abstract available

  510. REITHMEIER A, Panizza E, Krumpel M, Orre LM, et al
    Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFbeta2/TbetaR and CD44 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2017;17:650.
    PubMed     Abstract available

  511. REYNOLDS KL, Bedard PL, Lee SH, Lin CC, et al
    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
    BMC Cancer. 2017;17:646.
    PubMed     Abstract available

  512. HUSSAIN AR, Siraj AK, Ahmed M, Bu R, et al
    XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
    BMC Cancer. 2017;17:640.
    PubMed     Abstract available

  513. DEB S, Gorringe KL, Pang JB, Byrne DJ, et al
    BRCA2 carriers with male breast cancer show elevated tumour methylation.
    BMC Cancer. 2017;17:641.
    PubMed     Abstract available

    May 2017
  514. VOELS B, Wang L, Sens DA, Garrett SH, et al
    The unique C- and N-terminal sequences of Metallothionein isoform 3 mediate growth inhibition and Vectorial active transport in MCF-7 cells.
    BMC Cancer. 2017;17:369.
    PubMed     Abstract available

  515. DEMOOR-GOLDSCHMIDT C, Drui D, Doutriaux I, Michel G, et al
    A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme.
    BMC Cancer. 2017;17:326.
    PubMed     Abstract available

  516. BOGAN D, Meile L, El Bastawisy A, Yousef HF, et al
    The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    BMC Cancer. 2017;17:329.
    PubMed     Abstract available

  517. CHIN-QUEE K, Donahue HJ
    MDA-MET-conditioned-medium augments the chemoattractant-dependent migration of MDA-MET cells towards hFOB-conditioned medium and increases collagenase activity.
    BMC Cancer. 2017;17:324.
    PubMed     Abstract available

    April 2017
  518. JUNG SY, Sobel EM, Papp JC, Zhang ZF, et al
    Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women.
    BMC Cancer. 2017;17:290.
    PubMed     Abstract available

    March 2017
  519. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.